The short answer
Added harm from Plantago afra with semaglutide has not been established. The seed’s fluid and swallowing precautions and semaglutide’s gastrointestinal effects still need individual consideration.
What this answer covers
Plantago afra seed covered by the EMA seed monograph; not automatically psyllium husk from Plantago ovata.
- Supplement or preparation
- Plantago afra
- Medication ingredient
- semaglutide
The seed has its own precautions
The seed monograph requires adequate liquid and warns about swallowing difficulty and obstruction in unsuitable circumstances. These are intrinsic seed-use precautions, not a measured semaglutide interaction.
Semaglutide can affect the stomach
Semaglutide can cause substantial gastrointestinal symptoms and is not recommended in severe gastroparesis. These facts do not prove that adding this seed causes obstruction or quantify the combination’s risk.
Fit the instructions together
Oral semaglutide must be taken alone with its limited water amount and fasting interval. Do not mix bulk seed into that dose. The seed monograph also advises a half-to-one-hour gap from other medicines; ask the pharmacist to reconcile the product directions.
Symptoms need assessment
Seek clinical advice for trouble swallowing, severe or persistent abdominal symptoms, or inability to keep fluids down. A supplement should not be used to work around severe symptoms without assessment. The absence of a documented pair interaction is not a guarantee of safety.
Evidence and practical considerations
Side effects & toxicity
No exact-pair clinical evidence establishes the claimed change in semaglutide exposure, effectiveness or safety. Indirect preparation-specific findings and contrary/null results retained; general tablet administration is a separate finding.
- Exact scope
- Plantago afra seed covered by the EMA seed monograph; not automatically psyllium husk from Plantago ovata. with Semaglutide RxCUI 1991302 IN; exact oral-tablet and subcutaneous formulation boundaries.
- Medication form and route
- oral medication; subcutaneous medication; oral supplement
What remains uncertain
- No supplement-specific percentage, event rate, nutrient requirement or injection gap established.
Factors that may matter: Formulation; Preparation; Insulin or sulfonylurea co-use; Gastrointestinal symptoms.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Weekly subcutaneous dosing with or without meals. Glucose-dependent effects; hypoglycemia risk with insulin/secretagogues. Gastric emptying delayed but studied oral drugs had no clinically relevant absorption effect.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 4: original human pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 45 healthy participants in two-part study
Co-administration with placebo tablets reduced semaglutide exposure by 34%. Levothyroxine exposure increased in a different comparison.
How this applies: Supports oral administration conditions, not herb-specific pharmacokinetics or clinical harm.
Placebo tablets, not any named supplement. Not injected semaglutide or a proven percentage effect for current different tablet formulations. Abstract only.
Source 5: regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of the specified oral preparation.
Concomitant enteral medicine absorption may be delayed. Seed preparations should not be taken within one-half to one hour before or after other medicines; diabetic users require supervision because therapy may need adjustment.
How this applies: Indirect for semaglutide; exact original exposure, preparation and endpoint retained.
Plantago afra/indica seeds, not automatically Plantago ovata husk. General swallowing/obstruction and absorption precautions do not establish an added semaglutide bowel-injury rate.
Research assessment: · Open full citations ↗
Timing & monitoring
Oral semaglutide is taken fasting and at least 30 minutes before other oral products; this administration rule does not establish a botanical-specific interaction or apply to weekly injections.
- Exact scope
- Plantago afra seed covered by the EMA seed monograph; not automatically psyllium husk from Plantago ovata. with Current semaglutide tablets versus injections.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- Not a protective gap for all pharmacodynamic effects.
Factors that may matter: Formulation.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Weekly subcutaneous dosing with or without meals. Glucose-dependent effects; hypoglycemia risk with insulin/secretagogues. Gastric emptying delayed but studied oral drugs had no clinically relevant absorption effect.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 4: original human pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 45 healthy participants in two-part study
Co-administration with placebo tablets reduced semaglutide exposure by 34%. Levothyroxine exposure increased in a different comparison.
How this applies: Supports oral administration conditions, not herb-specific pharmacokinetics or clinical harm.
Placebo tablets, not any named supplement. Not injected semaglutide or a proven percentage effect for current different tablet formulations. Abstract only.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact semaglutide article distinguishing oral administration, injected treatment and supplement-specific evidence. | |
| Research summary published |
Article revision: 19e86eba9e70fa2d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.